[1] Pawlotsky JM. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology, 2015,148:468-479.
[2] Kai Y, Hikita H, Morishita N, et al. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep,2017,30:41660.
[3] Wang C, Sun JH, O'Boyle DR, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother,2013,57:2054-2065.
[4] Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol,2017,89:1248-1254.
[5] Hikita H, Sakamori R, Tahata Y,et al. Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology,2018,68:380-383.
[6] Wyles D, Dvory-Sobol H, Svarovskaia ES, et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol,2017,66:703-710. |
